Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

Savolitinib

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Savolitinib
Clinical data
Other namesVolitinib
ATC code
  • None
Identifiers
  • 3-[(1S)-1-Imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine
CAS Number
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard(EPA)
ECHA InfoCard100.238.920Edit this at Wikidata
Chemical and physical data
FormulaC17H15N9
Molar mass345.370 g·mol−1
3D model (JSmol)
  • C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21
  • InChI=1S/C17H15N9/c1-11(12-3-4-15-18-5-6-25(15)10-12)26-17-16(22-23-26)19-8-14(21-17)13-7-20-24(2)9-13/h3-11H,1-2H3/t11-/m0/s1
  • Key:XYDNMOZJKOGZLS-NSHDSACASA-N

Savolitinib is an experimental small molecule inhibitor ofc-Met. It is being investigated for the treatment of cancer byAstraZeneca.[1] It is in phase II clinical trials foradenocarcinoma,non-small cell lung cancer, andrenal cell carcinoma.[2] It has been given conditional approval for these indication in China.[3]

References

[edit]
  1. ^"Savolitinib"(PDF).Statement on a Nonproprietary Name Adopted by the USAN Council. American Medical Association. 26 October 2016.
  2. ^"Savolitinib - AstraZeneca/Hutchison China MediTech Limited".AdisInsight. Springer Nature Switzerland AG.
  3. ^Markham A (September 2021). "Savolitinib: First Approval".Drugs.81 (14):1665–1670.doi:10.1007/s40265-021-01584-0.PMID 34455538.S2CID 237344020.
CImonoclonal antibodies ("-mab")
Receptor tyrosine kinase
Others for solid tumors
Leukemia/lymphoma
Other
Tyrosine kinase inhibitors ("-nib")
Receptor tyrosine kinase
Non-receptor
Other
Products
Predecessors and
acquired companies
People
Portal:
Retrieved from "https://en.wikipedia.org/w/index.php?title=Savolitinib&oldid=1264703189"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp